BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Although it was returned to the market later because of the lack of effective alternatives for the treatment of CML patients with BCR-ABLT315I mutation, a black-box warning for arterial thrombotic events was labeled on this drug [6].